ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

NDRA vs VBIO // ENTERPRISE SCALE & MARKET CAP

ENDRA Life Sciences Inc. (NASDAQ) VS. Valion Bio Inc. (NASDAQ) • 15-METRIC TALLY: NDRA 3 — VBIO 0
▲ ENTERPRISE SCALE & MARKET CAP LEADER: NDRA
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NDRA VS. VBIO) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC NDRA VBIO SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 2/9 +1.00 NDRA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 42.0 20.1 +21.97 NDRA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap ACTIVE $7.3M $1.3M $6.0M NDRA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR NDRA REV VBIO REV NDRA GROSS % VBIO GROSS % NDRA FCF VBIO FCF
FY 2025 $0 $0 — — -$5.2M -$7.0M
FY 2024 $0 $780.0K — 0.3% -$7.4M -$5.7M
FY 2023 $0 $1.2M — — -$9.5M -$8.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NDRA // BETA —
VBIO // BETA —